Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

被引：4
|
作者：
Xu, R-H. [1 ]
Oh, D-Y. [2 ]
Kato, K. [3 ]
Arkenau, T. [4 ]
Tabernero, J. [5 ]
Cruz-Correa, M. [6 ]
Zimina, A. [7 ]
Bai, Y. [8 ]
Shi, J. [9 ]
Lee, K-W. [10 ]
Hirano, H.
Spigel, D. R. [11 ]
Wyrwicz, L. S. [12 ]
Cid, R. A. Pazo [13 ]
Li, L. [14 ]
Xu, Y. [15 ]
McHenry, M. B. [16 ]
Yang, S. [14 ]
Moehler, M. [17 ]
机构：
[1] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, Canc Ctr,State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Seoul Natl Univ, Hosp Canc Res Inst, Dept Internal Med, Coll Med, Seoul, South Korea
[3] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan
[4] Sarah Cannon Res Inst, Dept Drug Dev, London, England
[5] Vall dHebron Hosp Campus & Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[6] Univ Puerto Rico, Sch Med, San Juan, PR USA
[7] BIH Omsk Region, Dept Oncol, Clin Oncol Dispensary, Omsk, Russia
[8] Harbin Med Univ, Dept Gastrointestinal Oncol, Canc Hosp, Harbin, Peoples R China
[9] Linyi Canc Hosp, Dept Med Oncol 2, Linyi, Shandong, Peoples R China
[10] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi Do, South Korea
[11] Tennessee Oncol, Dept Thorac Med Oncol, Nashville, TN USA
[12] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Oncol & Radiotherapy, Warsaw, Poland
[13] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain
[14] BeiGene Beijing Co Ltd, Clin Dev Clin Biomarker, Beijing, Peoples R China
[15] BeiGene Shanghai Co Ltd, Clin Dev, Shanghai, Peoples R China
[16] BeiGene USA Inc, GSDS, Cambridge, MA USA
[17] Johannes Gutenberg Univ Clin, Dept Internal Med 1, Mainz, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA80
引用
收藏
页码：S1320 / S1321
页数：2
相关论文
共 50 条
  • [1] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, H-T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A. V.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
  • [2] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
    Kato, K.
    Xu, R-H.
    Oh, D-Y.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Xu, H.
    Sheng, T.
    Barnes, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
  • [3] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
    Cruz-Correa, Marcia
    Xu, Rui-Hua
    Moehler, Markus H.
    Oh, Do-Youn
    Kato, Ken
    Spigel, David R.
    Arkenau, Hendrik-Tobias
    Tabernero, Josep
    Zimina, Anastasia V.
    Bai, Yuxian
    Shi, Jianhua
    Lee, Keun-Wook
    Hirano, Hidekazu
    Wyrwicz, Lucjan S.
    Pazo Cid, Roberto
    Xu, Hui
    Sheng, Tao
    Barnes, Gisoo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 290 - 290
  • [4] Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: A post hoc analysis of RATIONALE-305 study.
    Qiu, Miaozhen
    Luo, Huiyan
    Wang, Feng-Hua
    Wang, Feng
    He, Ming-Ming
    Xu, Sheng
    Pan, Xiaoxi
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 414 - 414
  • [5] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
  • [6] Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.
    Arkenau, Hendrik-Tobias
    Tabernero, Josep
    Cruz-Correa, Marcia
    Zimina, Anastasia V.
    Poddubskaya, Elena
    Moiseenko, Fedor Vladimirovich
    Spigel, David R.
    Wyrwicz, Lucjan S.
    Disel, Umut
    Pazo Cid, Roberto
    Cubillo Gracian, Antonio
    Ales Diaz, Inmaculada
    Fornaro, Lorenzo
    Evesque, Ludovic
    Xu, Yaling
    Sheng, Tao
    Yang, Silu
    Li, Liyun
    Moehler, Markus H.
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 330 - 330
  • [7] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Campos Bragagnoli, A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Poulart, V.
    Cullen, D.
    Lei, M.
    Kondo, K.
    Li, M.
    Ajani, J. A.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
  • [8] First-line tislelizumab plus chemotherapy in gastric/ gastroesophageal junction cancer: RATIONALE-305 Asian Subgroup
    Kato, K.
    Bai, Y.
    Shi, J.
    Lee, K.
    Wang, J.
    Pan, H.
    Rha, S.
    Zhang, R.
    Hirano, H.
    Yamaguchi, K.
    Guo, Z.
    Ba, Y.
    Yang, L.
    Tsukuda, H.
    Xu, Y.
    Sheng, T.
    Yang, S.
    Li, L.
    Oh, D.
    Xu, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1316 - S1316
  • [9] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
    Lei, Ming
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Wang, Xuya
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Li, Mingshun
    Poulart, Valerie
    Wang, Yu
    Doshi, Parul
    Shitara., Kohei
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
    Janjigian, Y. Y.
    Ajani, J. A.
    Moehler, M.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Li, M.
    Poulart, V.
    Lei, M.
    Kondo, K.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
12345